Its been a quite couple of months in NSB land thats for sure, so this is some welcome news. For those who haven't already, worth revisiting the HealthKick Podcast: NSB brings new solutions to medicine’s most stubborn eye problems - from 14:12 there is approx. 3 mins of chat on the post Covid fibrosis arm of the business. This podcast was by the ex-Charmain in Feb this year. He mentions that after safety phase 1 in humans they can go into post Covid fibrosis patients... so still a while to go on this one yet perhaps. But lets see what they have to tell us with the TH
The pre-clinical data from Emtinb has all the hallmarks of a breakthrough drug. I think the market wants to see us get this thing into humans. Looking forward to trials beginning and will play the waiting game until Q1/Q2 next year when Glaucoma studies will hopefully return a banger of a result. Until then, happy to leave this one on hold while the company goes through the motions of making all of this happen
Cheers and GLTAH
NSB Price at posting:
31.5¢ Sentiment: Hold Disclosure: Held
